达罗他胺治疗转移性去势抵抗性前列腺癌1例报告  

Therapeutic regimen with darolutamide for metastatic castration resistant prostate cancer: a case report

作　　者：周智恩[1] 朱明 周毅[1] 严维刚[1] Zhou Zhien;Zhu Ming;Zhou Yi;Yan Weigang(Department of Urology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100730,China)

机构地区：[1]中国医学科学院北京协和医学院北京协和医院泌尿外科,北京100730

出　　处：《中华泌尿外科杂志》2022年第7期545-547,共3页Chinese Journal of Urology

摘　　要：达罗他胺用于治疗转移性去势抵抗性前列腺癌(mCRPC)的研究较少,本文报道1例。患者83岁,因排尿困难入院,初诊为转移性激素敏感性前列腺癌,采用雄激素剥夺治疗(ADT)+比卡鲁胺治疗。半年后复查骨扫描提示新发转移灶>2处,考虑进入mCRPC。因患者高龄,既往有癫痫、2型糖尿病及心脏射频消融术病史,长期服用苯巴比妥及瑞格列奈,存在用药禁忌,改为ADT联合达罗他胺治疗。10个月后复查骨扫描示部分转移灶代谢减低,tPSA持续下降。There are few studies about the treatment of metastatic castration-resistant prostate cancer(mCRPC)with darolutamide.This paper reports a case that an 83-year-old patient complained of dysuria.His initial diagnosis was metastatic hormone sensitive prostate cancer(mHSPC).Androgen deprivation therapy(ADT)plus bicalutamide was performed.Re-examination of bone scan after half a year revealed that there were more than two new bone metastases,which was considered entering mCRPC.Due to the patient’s advanced age,post medical history of epilepsy,type 2 diabetes and cardiac radiofrequency ablation,long-term use of phenobarbital and repaglinide,the therapy was changed to ADT plus darolutamide to avoid drug contraindications.Re-examination of bone scan after 10 months revealed decreased metabolism in some metastases,and tPSA declined continuously.

关 键 词：前列腺肿瘤 癌 转移性 去势抵抗性 达罗他胺 

分 类 号：R737.25[医药卫生—肿瘤]